There is one clinical trial.
This is an open-label, randomized, phase II study with the main objective to investigate the effectiveness and safety of an investigational drug (APG101; International Nonproprietary Name: asunercept) in patients with severe COVID-19 disease. The study aims to decrease overall and SARS-CoV-2 associated pneumonia mortality in patients with COVID-19 as well as to decrease the percentage of patients admitted to Intensive Care Unit (ICU), decrease the need to supply oxygen to patients, reduce the number of days patients are hospitalized in ICU and/or on the ward, decrease the number of days required to obtain a negative result in the PCR (Polymerase Chain Reaction, a laboratory technique that allows the amplification of small fragments of DNA to detect the presence of the virus) test for COVID-19 and decrease the levels of markers that indicate pneumonia.
Description: The primary endpoint is time to clinical improvement which is defined as time from randomisation to an (sustained) improvement of at least one category on two consecutive days compared to the status at randomisation measured on a nine-category ordinal scale (proposed by WHO).Measure: Time to sustained improvement of one category (i.e. two consecutive days) from randomisation Time: Day 1-29
Description: Time to discharge or to a NEWS of ≤2 and maintained for 24 hours, whichever occurs first Change from baselineMeasure: Efficacy according to the National Early Warning Score (NEWS) Time: Day 1-29
Description: Oxygenation free days until day 29 Incidence and duration of new oxygen use during the trialMeasure: Oxygenation Time: Day 1-29
Description: Ventilator free days until day 29 Incidence and duration fo new mechanical ventilation use during the trialMeasure: Ventilation Time: Day 1-29
Description: Duration of hospitalisation Length of ICU stay (in days)Measure: Hospitalisation - Length Time: Day 1-29
Description: Proportion of patients admitted to ICUMeasure: Hospitalisation - Proportion on ICU Time: Day 1-29
Description: 15-day, 29-day all-cause mortalityMeasure: Mortality Time: Day 1-29
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports